The effect of platelet inhibitory therapy on graft thromboresistance.
Greyhounds (n = 38) were randomized to aspirin and dipyridamole (ASA + DPM), the thromboxane synthetase inhibitor (TSI) CGS12970 (CIBA-GEIGY) or placebo twice daily for 48 hours prior to bilateral implantation of femoral artery Dacron grafts. In-vivo 111In-platelet deposition on grafts was measured at 5 days and 2 months. Grafts were removed at 2 months when ex-vivo graft and arterial release of 6-ketoprostaglandin F1a (6-keto PGF1a) was measured by radioimmunoassay. Graft 6-keto-PGF1a was significantly increased by CGS12970 but ASA + DPM had no significant effect. ASA + DPM significantly reduced arterial 6-keto-PGF1a although this was marginally increased by CGS12970. Neither active treatment reduced in-vivo 111In-platelet deposition. Preservation of vascular or graft prostacyclin by thromboxane synthetase inhibitors may represent an alternative strategy in preventing prosthetic graft thrombosis.
Bearn
P E
PE
Bloomsbury Vascular Unit, Middlesex Hospital, London, UK.
Bull
H
H
Seddon
A M
AM
Marston
A
A
McCollum
C N
CN
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000818:Animals; D001241:Aspirin / Q000627:therapeutic use*; D001807:Blood Vessel Prosthesis; D004176:Dipyridamole / Q000627:therapeutic use*; D004285:Dogs; D004359:Drug Therapy, Combination; D005260:Female; D005263:Femoral Artery / Q000000981:diagnostic imaging / Q000378:metabolism / Q000601:surgery; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D011725:Pyridines / Q000627:therapeutic use*; D011859:Radiography; D011897:Random Allocation; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D011725:Pyridines; D015121:6-Ketoprostaglandin F1 alpha; D004176:Dipyridamole; C049113:3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid; D013930:Thromboxane-A Synthase; D001241:Aspirin